InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update
August 08, 2024 07:30 ET
|
InflaRx N.V.
Hosted research and development (R&D) event focused on the differentiation of INF904 and its potential in addressing significant unmet needs in inflammation & immunology (I&I)Initiation of...
InflaRx Hosts R&D Event Highlighting the Promise of INF904
June 05, 2024 12:00 ET
|
InflaRx N.V.
Thought leaders in complement inhibition, chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) provide compelling new insights into the strong development rationales, potential...
Global Vitiligo Treatment Market 2023: Unpacking the Potential of Antihistamines, H2 Antagonists and Tricyclic Antidepressants
October 30, 2023 05:43 ET
|
Research and Markets
Dublin, Oct. 30, 2023 (GLOBE NEWSWIRE) -- The "Vitiligo Treatment Global Market Report 2023" has been added to ResearchAndMarkets.com's offering. The global vitiligo treatment market is expected...